Nexalin Technology shares are trading higher after the company was awarded a US patent on 'Transcranial alternating current dynamic frequency stimulation (TACS) method for Alzheimers and Dementia.'
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology shares are trading higher after the company was awarded a US patent on 'Transcranial alternating current dynamic frequency stimulation (TACS) method for Alzheimer's and Dementia.'
June 18, 2024 | 7:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology shares are experiencing a boost following the award of a US patent for its TACS method aimed at treating Alzheimer's and Dementia.
The award of a US patent for a novel treatment method is a significant milestone for Nexalin Technology, likely to boost investor confidence and drive short-term stock price gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100